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David St´ıbal,a Lennart Geiser,b Georg Su¨ss-Finka and Julien Furrer*b
The hydrolysis and the reactivity of two dinuclear p-cymene ruthenium monothiolato complexes, [(h6-p-
MeC6H4Pr
i)2Ru2Cl2(m-Cl)(m-S-m-9-B10C2H11)] (1) and [(h
6-p-MeC6H4Pr
i)2Ru2Cl2(m-Cl)(m-SCH2-p-C6H4–
NO2)] (2), and of two dinuclear p-cymene ruthenium dithiolato complexes, [(h
6-p-MeC6H4Pr
i)2Ru2(m-
SCH2CH2Ph)2Cl2] (3) and [(h
6-p-MeC6H4Pr
i)2Ru2(SCH2C6H4-p-OMe)2Cl2] (4) towards amino acids,
nucleotides, and a single-stranded DNA dodecamer were studied using NMR and mass spectrometry. In
aqueous solutions at 37 C, the monothiolato complexes 1 and 2 undergo rapid hydrolysis, irrespective
of the pH value, the predominant species in D2O/acetone-d6 solution at equilibrium being the neutral
hydroxo complexes [(h6-p-MeC6H4Pr
i)2Ru2(OD)2(m-OD)(m-SR)]. The dithiolato complexes 3 and 4 are
stable in water under acidic conditions, but undergo slow hydrolysis under neutral and basic conditions.
In both cases, the cationic hydroxo complexes [(h6-p-MeC6H4Pr
i)2Ru2(OD)(CD3CN)(m-SR)2]
+ are the only
species observed in D2O/CD3CN at equilibrium. Surprisingly, no adducts are observed upon addition of
an excess of L-methionine or L-histidine to the aqueous solutions of the complexes. Upon addition of an
excess of L-cysteine, on the other hand, 1 and 2 form the unusual cationic trithiolato complexes [(h6-p-
MeC6H4Pr
i)2Ru2{m-SCH2CH(NH2)COOH}2(m-SR)]
+ containing two bridging cysteinato ligands, while 3 and
4 yield cationic trithiolato complexes [(h6-p-MeC6H4Pr
i)2Ru2[m-SCH2CH(NH2)COOH](m-SR)2]
+ containing
one bridging cysteinato ligand. A representative of cationic trithiolato complexes containing a cysteinato
bridge of this type, [(h6-p-MeC6H4Pr
i)2Ru2[m-SCH2CH(NH2)COOH](m-SCH2-p-C6H4-Bu
t)2]
+ (6) could be
synthesised from the dithiolato complex [(h6-p-MeC6H4Pr
i)2Ru2(SCH2C6H4-p-Bu
t)2Cl2] (5), isolated as
the tetraﬂuoroborate salt and fully characterised. Moreover, the mono- and dithiolato complexes 1–4
are inert toward nucleotides and DNA, suggesting that DNA is not a target of cytotoxic thiolato-bridged
arene ruthenium complexes. In contrast to the trithiolato complexes, monothiolato and dithiolato
complexes hydrolyse and react with L-cysteine. These results may have important implications for the
mode of action of thiolato-bridged dinuclear arene ruthenium drug candidates, and suggest that their
modes of action are diﬀerent to those of other arene ruthenium complexes.1. Introduction
Ever since the serendipitous discovery of the anticancer prop-
erties of cisplatin in 1965 1 and its clinical use in 1978,2 the
research on platinum cytostatics has ourished. A plethora of
analogous square-planar platinum(II) and octahedral plati-
num(IV) complexes was synthesised and studied in order to nd
more selective and less toxic alternatives.3 Despite immense
eﬀorts, only two additional platinum complexes were approved
for global use in the clinic so far: the second-generation drug
carboplatin was approved by the FDA in 1989 and the third-, CH-2000 Neuchaˆtel, Switzerland
ie, Universita¨t Bern, CH-3012 Bern,
e.ch; Fax: +41 31 631 48 87
tion (ESI) available. See DOI:
41generation oxaliplatin in 2002.4 Unfortunately, none of the
three agents possess very high selectivity towards cancerous
cells; their therapeutic application therefore causes severe side
eﬀects such as nephrotoxicity,5–7 neurotoxicity8,9 and nausea.8,10
In order to overcome these side-eﬀects, part of the research on
metallodrugs has shied from platinum to ruthenium-based
anticancer agents. Ruthenium compounds have in general
lower systemic toxicity than platinum drugs, they can access
a wide range of oxidation states under physiological conditions
and have a very similar ligand exchange rate as platinum
complexes.11 The eld of anticancer ruthenium compounds was
pioneered by Alessio, Sava and Keppler, who developed ruth-
enium(III) imidazole and indazole complexes, the imidazolium
or indazolium salts of which (termed NAMI-A and KP1019,
respectively) have already entered clinical trials.12–15 The sodium
analogue of KP1019, termed NKP-1339, is now on the edge of
clinical application.16This journal is © The Royal Society of Chemistry 2016
Scheme 1 Stepwise synthesis of thiolato-bridged arene ruthenium
complexes.42
Fig. 1 Structures of complexes 1–4, the symbolsC in the formula of 1
represent CH groups of the carborane moiety.
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View Article OnlineIn 1992, Tocher and co-workers have observed a cytotoxicity
enhancement by coordinating the anticancer agent metronida-
zole [1-b-(hydroxyethyl)-2-methyl-5-nitro-imidazole] to a benzene
ruthenium dichlorido fragment.17 Subsequently, it became
obvious that water-soluble arene ruthenium complexes are in
general cytotoxic, since they seem to have the right balance
between lipophilicity and hydrophilicity, essential for cellular
uptake.18 The rst prototype arene ruthenium(II) complexes eval-
uated for anticancer properties in 2001 were [(h6-p-MeC6H4Pr
i)
Ru(P-pta)Cl2] (pta ¼ 1,3,5-triaza-7-phosphaadamantane), termed
RAPTA-C, from Dyson's laboratory19 and the RAED family of
compounds [(h6-C6H5Ph)Ru-(N,N-en)Cl]
+ as hexauorophosphate
or chloride salt from Sadler's laboratory.20 Importantly, although
RAPTA-C only exhibits a low activity in vitro, it is very active in vivo,
where it inhibits lung metastases in CBA mice.21 Therefore,
RAPTA-C can be considered as an antimetastatic agent like NAMI-
A.21,22 RAED compounds are highly cytotoxic to a range of cancer
cell lines,23 including cisplatin-resistant cell lines. An in vivo study
established that RM175, [(h6-C6H5Ph)Ru(N,N-en)Cl]PF6, is active
against MCa mammary carcinoma and causes metastasis reduc-
tion.24 In addition to these two prototype compounds, a plethora
of organometallic ruthenium(II) compounds have been prepared
and their cytotoxicity to cancer cells examined.25–33
In recent years, we have synthesised several series of dinu-
clear arene ruthenium thiolato-bridged complexes of the
general formula [(h6-arene)2Ru2(m-SR)3]Cl that are highly cyto-
toxic against ovarian cancer cell lines A2780 and A2780cisR, the
most active derivative [(h6-p-MeC6H4Pr
i)2Ru2(m-S-p-C6H4Bu
t)3]Cl
(diruthenium-1) having an IC50 value of 30 nM to both cell
lines.34–39 To the best of our knowledge, diruthenium-1 is the
most cytotoxic arene ruthenium compound reported to date. A
recent in vivo study has demonstrated that dinuclear arene
ruthenium thiolato-bridged complexes have the potential to
become anticancer chemotherapy agents, since diruthenium-1
signicantly prolongs the survival of tumour-bearing mice.40
By varying the synthetic procedure, we succeeded in isolating
neutral dithiolato complexes of the type [(h6-p-MeC6H4Pr
i)2-
Ru2(m-SR)2Cl2]41 and subsequently alsomonothiolato complexes
of the general formula [(h6-p-MeC6H4Pr
i)2Ru2Cl2(m-Cl)(m-SR)],42
intermediates in the formation of the cationic trithiolato
complexes, thus opening new avenues for the ne-tuning the
properties of dinuclear thiolato-bridged arene ruthenium
complexes (Scheme 1).43
Interestingly, the mono- and dithiolato analogues are system-
atically at least one order of magnitude less cytotoxic than their
trithiolato counterparts.36,38,39 The stability and reactivity studies
of some trithiolato complexes with various amino acids, peptides,
nucleotides and DNA revealed that the complexes are very stable
in physiological conditions as well as under acidic and basic
conditions and that they are particularly inert towards substitu-
tion. Only the sulphur-containing biomolecules cysteine (Cys) and
the tripeptide glutathione (GSH) interact with the complexes.
Unexpectedly, no adducts were identied, but Cys and GSH
undergo a catalytic oxidation in the presence of the trithiolato
complexes, forming cystine and GSSG.35 Such a mode of action
has already been proposed for arene ruthenium azopyridine iodo
complexes, which are surprisingly cytotoxic despite their inertnessThis journal is © The Royal Society of Chemistry 2016to ligand substitution.44 Although a decrease in the glutathione
levels with increasing concentration of diruthenium-1 was
observed in vitro and in vivo,40 no direct correlation between their
cytotoxicity and catalytic activity for the oxidation of glutathione
was found.36,38,39 We therefore assume that other mechanisms are
mainly responsible for the high in vitro cytotoxicity of the tri-
thiolato complexes.
In an eﬀort to rationalise the relationship between reactivity
and the in vitro cytotoxicity of thiolato-bridged arene ruthenium
complexes, we set out to investigate the hydrolysis of two
monothiolato complexes 1 and 2 and two dithiolato complexesRSC Adv., 2016, 6, 38332–38341 | 38333
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View Article Online3 and 4 (Fig. 1) as well as their interactions with selected amino
acids, nucleotides and a single-stranded DNA dodecamer.2. Results and discussion
2.1. Stability of the monothiolato complexes 1 and 2 in
aqueous solution
Fig. 2 shows the 1D 1H-NMR spectra of 1 dissolved in a D2O/
acetone-d6 mixture (ratio 7 : 3) at pD 7, recorded at 37 C
between 5 min and 24 h. Additional resonances appeared
immediately aer sample preparation, indicating rapid hydro-
lysis, and equilibrium is reached aer about 1 h. Analysis of the
doublets for the p-cymene ring protons suggests that three
species are present in solution. One with resonances at d ¼ 5.53
and 5.80 ppm is identied as 1, and a second one with four
resonances at d ¼ 5.11, 5.27, 5.62 and 5.72 ppm is attributed to
a species that underwent chloro/aqua exchange. This species,
which is the most abundant one present in solution aer 1 h, is
assumed to be the neutral hydroxo complex [(h6-p-MeC6H4-
Pri)2Ru2(OD)2(m-OD)(m-S-m-9-B10C2H11)] (Scheme S1†). The high
symmetrical nature of this fully hydrolysed complex is supported
by the single 1H-NMR resonances observed for the p-cymene
protons in the high eld region of the 1H-NMR spectrum
(Fig. S1†). For the hypothetical mixed hydroxo-chloro complex
[(h6-p-MeC6H4Pr
i)2Ru2(OD)(Cl)(m-OD)(m-S-m-9-B10C2H11)], two sets
of resonances would be observed for these protons. The fact that
four resonances are observed for the p-cymene ring protons is notFig. 2 The p-cymene ring proton region of the 1H NMR spectrum of
[(h6-p-MeC6H4Pr
i)2Ru2Cl2(m-Cl)(m-S-m-9-B10C2H11)] (1) dissolved in
D2O/acetone-d6 (ratio 7 : 3) , recorded between t¼ 5 min and t¼ 24 h
at 37 C and at pD 7. The labels correspond to p-cymene ligands in
diﬀerent species present in solution. The species labeled * corre-
sponds to complex 1, the species labeled > is presumably the fully
hydrolysed species [(h6-p-MeC6H4Pr
i)2Ru2(OD)2(m-OD)(m-S-m-9-
B10C2H11)], while the species labeled with C has not been further
characterised.
38334 | RSC Adv., 2016, 6, 38332–38341surprising. The molecular structures of several dinuclear
trithiolato-bridged ruthenium complexes, which are apparently
highly symmetrical, show that the two ruthenium atoms adopt
a pseudo-octahedral geometry.36 Consequently, four doublets
caused by the eight aromatic protons of the two p-cymene rings
are oen present in the region between 4.90 and 6.00 ppm.39 A
third, minor species with resonances at d ¼ 5.50, 5.62, 5.73, 5.82,
5.96 and 6.00 ppm is also present in the mixture immediately
aer sample preparation. A full characterisation was not
attempted due to its very low concentration. However, since six p-
cymene ring proton resonances and four methyl resonances
between 1.10 and 1.32 ppm in the high eld region of the 1H-NMR
spectrum (Fig. S1†) are observed for this species, it may be
assumed that it is a mixed hydroxo-chloro complex, for instance
[(h6-p-MeC6H4Pr
i)2Ru2(OD)(Cl)(m-OD)(m-S-m-9-B10C2H11)].
Similar results are obtained for 2, however, the hydrolysis is
signicantly faster, and the equilibrium is already reached aer
5 min since no further changes in the NMR spectra are noticed
subsequently (Fig. S2†). In order to study the suppression of
hydrolysis by chloride ions, the same series of NMR spectra of
both complexes were recorded in 105 mM NaCl solution. No
spectral changes are observed, indicating that aquation is
inhibited and that the observed products are indeed hydrolysed
species. These results indicate that 1 and 2, unless metabolised
in a diﬀerent way, e.g. by protein binding, should survive the
conditions in the bloodstream and that the hydrolysis could
take place inside the cells where the chloride concentration
decreases to ca. 4 mM.
The formation of the hydroxo complexes [(h6-p-MeC6H4-
Pri)2Ru2(OH)2(m-OH)(m-SR)] by hydrolysis could be supported by
ESI-MS measurements. The ESI-MS spectra of 1 and 2 dissolved
in aqueous solutions at pH 7 recorded aer 24 h show in each
case a single group of peaks centred atm/z¼ 681.19 for 1 and at
m/z ¼ 674.05 for 2, respectively (Fig. S3 & S4†), obtained most
likely by loss of a single hydroxo ligand from the fully hydro-
lysed complexes [(h6-p-MeC6H4Pr
i)2Ru2(OH)2(m-OH)(m-SR)]. In
addition, there is no evidence for the formation of chloro-
hydroxo complexes in both ESI-MS spectra. At pH ¼ 4, the
hydrolysis proceeds much slower (Fig. S5 & S6†) and the ESI-MS
spectra of both complexes recorded aer 24 h show the starting
complex [(h6-p-MeC6H4Pr
i)2Ru2Cl2(m-Cl)(m-SR)], revealed by the
group of peaks centred atm/z¼ 717.12 for 1 (Fig. S5†) and atm/z
¼ 709.1 for 2, (Fig. S6†), and themonohydroxo complexes [(h6-p-
MeC6H4Pr
i)2Ru2Cl(OH)(m-Cl)(m-SR)], revealed by the group of
peaks centred at m/z ¼ 699.16 for 1 and at m/z ¼ 692.01 for 2.
Interestingly, for 2, a group of peaks centred at m/z ¼ 842.2
corresponding to the dithiolato complex [(h6-p-MeC6H4Pr
i)2-
Ru2Cl(m-SCH2-p-C6H4–NO2)2] is also visible the ESI-MS spec-
trum. The formation of a dithiolato complex during hydrolysis
is not surprising, since equilibria between the thiolato
complexes and the thiol have been evidenced.42,43 The coordi-
nated thiolato bridge can come oﬀ as thiol to be replaced by
a thiolato bridge derived from another thiol, which leads to
a mixture of thiolato complexes. These equilibria are governed
mostly by the reactivity of the thiols and to a lesser extent by the
choice of the solvent and reaction conditions.42This journal is © The Royal Society of Chemistry 2016
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View Article Online2.2. Stability of the dithiolato complexes 3 and 4 in aqueous
solution
Fig. 3 shows the 1D 1H-NMR spectra of 3 dissolved in a mixture
D2O/CD3CN (ratio 7 : 3) recorded at 37 C and at pD 7, between
5 min and 24 h. Additional resonances appear immediately,
indicating that 3 undergoes chloro/aqua exchange. However,
contrary to what has been found for the monothiolato
complexes 1 and 2, the hydrolysis of 3 is slow and not complete
before 24 h (Fig. 3). Analysis of the doublets for the p-cymene
ring protons suggests that at least three species are present in
the solution. The species with broad resonances at d ¼ 5.41 and
5.54 ppm is identied as 3. The main species present aer 24 h
with four resonances at d ¼ 5.28, 5.32, 5.34 and 5.41 ppm is
assumed to be the cationic hydroxo–acetonitrile complex [(h6-p-
MeC6H4Pr
i)2Ru2(OD)(CD3CN)(m-S-C2H4Ph)2]
+, in which one
chlorido ligand is replaced by one hydroxo ligand, while the
second one is replaced by a molecule of acetonitrile (Fig. 3, S7
and Scheme S2†). The formation of the cationic hydroxo–
acetonitrile complex [(h6-p-MeC6H4Pr
i)2Ru2(OD)(CD3CN)(m-S-
C2H4Ph)2]
+ with a lower symmetry is further supported by the
two sets of 1H-resonances of equal intensity observed for the p-Fig. 3 The p-cymene ring proton region of the 1H NMR spectrum of
[(h6-p-MeC6H4Pr
i)2Ru2(m-SC2H4Ph)2Cl2] (3) dissolved in D2O/CD3CN
(ratio 6 : 4) recorded between t¼ 5min and t¼ 24 h at 37 C and at pD
7. The labels correspond to p-cymene ligands in diﬀerent species
present in solution. The species labeled * corresponds to the complex
3, the species labeled > is assumed to be the hydroxo–acetonitrile
complex [(h6-p-MeC6H4Pr
i)2Ru2(OD)(CD3CN)(m-S-C2H4Ph)2]
+, while
the species labeled with C and , have not been further
characterised.
This journal is © The Royal Society of Chemistry 2016cymene protons in the high eld region of the 1H-NMR spec-
trum (Fig. S7†). Two other minor species with resonances at d ¼
5.63 and 5.76 ppm as well as at d ¼ 5.59 and 5.82 ppm can be
observed in the mixture immediately aer sample preparation,
but disappear gradually and are not visible aer 5 h. Due to
their low concentration and transient character, further char-
acterisation was not attempted. The stability of 3 in CD3CN was
also evaluated; the NMR spectra show that 3 remains stable for
at least 48 hours. Hydrolysis of 3 at pH 7 was supported by the
ESI-MS spectrum, which shows a single group of peaks centred
atm/z¼ 808.17 corresponding to the hydrolysed complex [(h6-p-
MeC6H4Pr
i)2Ru2(OH)(CH3CN)(m-S-C2H4Ph)2]
+ (Fig. S8†).
The kinetic experiment was repeated at pD ¼ 11 aer addi-
tion of NaOD. Analysis of the doublets for the p-cymene ring
protons show that, apart form 3 with broad resonances at d ¼
5.41 and 5.54 ppm, the hydroxo–acetonitrile complex [(h6-p-
MeC6H4Pr
i)2Ru2(OD)(CD3CN)(m-S-C2H4Ph)2]
+ with four reso-
nances at d ¼ 5.28, 5.32, 5.34 and 5.41 ppm is present in the
mixture. Intriguingly, the equilibrium is reached only aer 48 h
(Fig. S9†). The same experiment was repeated at pD 2 aer
addition of DCl. Weak additional resonances can be detected
directly aer sample preparation, suggesting a rapid hydrolysis
or the presence of a second unknown species. However, the
equilibrium is reached immediately, as no further changes are
visible in the subsequent NMR spectra recorded between t ¼ 5
min and t ¼ 24 h (Fig. S10†). Analysis of the 1H NMR spectra
shows that 3 is the major species present in the mixture.
In the case of 4, additional resonances also appeared
immediately aer sample preparation, indicating rapid hydro-
lysis, and the equilibrium is reached rapidly aer about 2 h
(Fig. 4). The species with two broad resonances at d ¼ 5.30 and
5.38 ppm is identied as 4. The main species at equilibrium
with four resonances at d ¼ 4.78, 4.83, 5.05 and 5.18 ppm is
assumed to be the hydroxo–acetonitrile complex [(h6-p-MeC6-
H4Pr
i)2Ru2(OD)(CD3CN)(m-S–CH2–C6H4-p-OMe)2]
+, similar to
that observed with 3. Two further species with resonances at d¼
5.20 and 5.49 ppm as well as at d ¼ 5.59 ppm are also observed
in the mixture immediately aer sample preparation, but
disappear progressively and are not visible aer 2 h. Due to their
low concentration and transient character, a further character-
isation was not attempted. Hydrolysis of 4 at pH 7 was
conrmed by the ESI-MS spectrum, which shows a single group
of peaks centred at m/z ¼ 840.16 that matches the hydroxo–
acetonitrile complex [(h6-p-MeC6H4Pr
i)2Ru2(OH)(CH3CN)(m-S–
CH2–C6H4-p-OMe)2]
+ (Fig. S11†).
The kinetic experiment was repeated at pD 11 aer addition
of NaOD. Analysis of the doublets for the p-cymene ring protons
show that 4 with broad resonances at d ¼ 5.28 and 5.36 ppm,
and the hydroxo–acetonitrile complex [(h6-p-MeC6H4Pr
i)2Ru2(-
OD)(CD3CN)(m-S–CH2–C6H4-p-OMe)2]
+ with four resonances at
d ¼ 4.77, 4.82, 5.06 and 5.19 ppm are present in the mixture.
Intriguingly, as observed with 3, the equilibrium is not reached
before 48 h (Fig. S12†). The experiment repeated at pD 2 aer
addition of DCl shows that weak additional resonances
appeared directly aer sample preparation, indicating a rapid
hydrolysis, but equilibrium is reached immediately. Analysis ofRSC Adv., 2016, 6, 38332–38341 | 38335
Fig. 4 The p-cymene ring proton region of the 1H NMR spectrum of
[(h6-p-MeC6H4Pr
i)2Ru2(m-SCH2–C6H4-p-OMe)2Cl2] (4) dissolved in
D2O/CD3CN (ratio 6 : 4) recorded between t¼ 5min and t¼ 24 h at 37
C and at pD 7. The labels correspond to p-cymene ligands in diﬀerent
species present in solution. The species labeled * corresponds to 4, the
species labeled> is assumed to be the hydroxo–acetonitrile complex
[(h6-p-MeC6H4Pr
i)2Ru2(OD)(CD3CN)(m-S–CH2–C6H4-p-OMe)2]
+,
while the species labeled with C and , have not been further
characterised.
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View Article Online1H NMR spectra shows that 4 is the major species present in the
mixture (Fig. S13†).Fig. 5 2D-1H DOSY spectrum of the mixture 1 : Ala (ratio 1 : 3) dis-
solved in D2O/acetone-d6 (ratio 7 : 3) recorded after 24 h at 37 C.2.3. Reactivity of 1–4 with nucleotides and DNA
In general, arene ruthenium compounds have been shown to
bind to DNA model compounds45,46 via loss of the chlorido
ligands, and loss of the arene was also observed. More impor-
tantly, by using a 14-mer oligonucleotide, it has not been
possible to identify preferential binding sites, due to the
multiple interactions that are available.
Upon addition of 3 eq. of dAMP and dGMP, no changes in
the NMR spectra are observed for complexes 2 and 3. As an
example, the 2D-1H DOSY NMR spectrum of the mixture
3 : dGMP (ratio 1 : 3) recorded aer 24 h is shown in Fig. S14.†
In the spectrum two species can be identied: one with the
lowest diﬀusion coeﬃcient being the hydrolysed derivative of 3,
and the second species being free dGMP. Furthermore,
inspection of the 1D 1H and 2D-1H DOSY NMR spectra shows
a single H8 resonance at d 8.22 ppm for dGMP, suggestive of the
absence of a coordination of N7 to the Ru atom.
In order to investigate possible reactions with DNA, the
complexes 1–4 were incubated at 37 C together with the single-
stranded DNA 20-mer (CGCGATCGCGGCGCTAGCGC) for 24 h.
In analogy with platinum complexes and some other ruthenium
compounds,20,42,47,48 we assumed that complexes 1–4 could bind
to the nucleophilic nitrogen of the nucleotides once they38336 | RSC Adv., 2016, 6, 38332–38341underwent hydrolysis. However, ESI mass spectroscopy spectra
recorded in the negative and positive mode (Fig. S15†) revealed
that no adducts are formed between the mono- and dithiolato
complexes and the single-stranded DNA 20-mer. Interestingly,
we have previously shown that trithiolato complexes are also
inert towards nucleotides and DNA.35,36 As such, unlike other
arene ruthenium complexes, these results suggest that DNA is
not a target of thiolato-bridged arene ruthenium complexes and
that they exert their cytotoxicity through other mechanisms.2.4. Reactivity of 1–4 with aspartic acid, alanine and
histidine
Most of the metallodrugs currently used in antitumoural
therapy, such as carboplatin and cisplatin, are administered
intravenously and can therefore encounter various reactive
biomolecules in the bloodstream.20,47 Interactions with peptides
and serum proteins can have a pronounced inuence on the
drug distribution, bioavailability and target or oﬀ-target eﬀects.
To investigate some of these possible interactions, the neutral
amino acid Ala, the acidic amino acid Asp and the basic amino
acid His were used. His was also chosen to investigate a possible
binding between the imidazole ring and the ruthenium atom,
since we and others already showed that imidazole rings
strongly and rapidly interact with the ruthenium atom49–54 and
especially with arene ruthenium complexes.55–58
Alanine usually does not react with ruthenium complexes,
although a hexacationic arene ruthenium assembly possessing
an oxalato linker slowly degrades in the presence of excess of Ala
to give mononuclear ruthenium-alanine adducts.53 Asp with
a coordinating carboxyl side chains is known to form tridentate
chelate complexes with ruthenium and other metal
centres.54,55,59 Upon addition of 3 eq. of Ala and Asp, no changes
in the NMR spectra are observed for the four complexes 1–4
(Fig. 5, S16 and S17†). As an example, the 2D-1H DOSY NMR
spectrum of the mixture 1 : Ala (ratio 1 : 3) recorded aer 24 h is
shown in Fig. 5. In the spectrum four species can be clearly
distinguished: two, with the lowest diﬀusion coeﬃcient, being
complex 1 and the hydrolysed derivative thereof, the third
species being free Ala, and the fourth one acetone.This journal is © The Royal Society of Chemistry 2016
Fig. 6 2D-1H DOSY spectrum of the mixture 3 : His (ratio 1 : 3) dis-
solved in D2O/CD3CN (ratio 6 : 4) recorded after 24 h at 37 C.
Fig. 7 ESI-MS spectrum of the mixture 2 : His (ratio 1 : 3) dissolved in
an acetone-d6/D2O mixture (ratio 3 : 7) recorded after 24 h. The
structures of the corresponding species are indicated on top of each
peak.
Fig. 8 2D-1H DOSY spectrum of the mixture 1 : Cys (ratio 1 : 2) dis-
solved in D2O/acetone-d6 (ratio 7 : 3) recorded after 24 h at 37 C.
Both aH resonances of Cys are highlighted with a circle.
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View Article OnlineFurthermore, inspection of the 1D 1H and 2D-1H DOSY NMR
spectra shows a single aH resonance and a single bCH3 reso-
nance for Ala, suggestive of the absence of a coordination of Ala
to the Ru atom.
Upon addition of 3 eq. of His, surprisingly, both NMR and ESI
mass spectrometry data strongly suggest that the mono- and
dithiolato complexes 1–4 do not react with His (Fig. 6 and S18†).
As an example, the 2D-1H DOSY spectrum of the mixture 3 : His
(ratio 1 : 3) recorded aer 24 h is shown in Fig. 6. In the spectrum
two species can be clearly distinguished: one with the lowest
diﬀusion coeﬃcient being the hydrolysed derivative of complex 3,
the second one being free His. Furthermore, inspection of the 1D
1H and 2D-1H DOSY NMR spectra shows for His a single aH
resonance, two bCH2 resonances for the two bH diastereotopic
protons and especially only two CH resonances for the imidazole
group, suggestive of the absence of a coordination of the imid-
azole ring of His to the Ru atom. The ESI-MS spectrum of the
mixture 2 : His (ratio 1 : 3) recorded aer 24 h shown in Fig. 7
conrms the absence of a coordination of His to the Ru atom. The
groups of peaks observed in the ESI-MS spectrum at m/z ¼ 692.2,
709.1, and 842.2, respectively, are identical to those observed aerThis journal is © The Royal Society of Chemistry 2016the hydrolysis of 2 and correspond the monohydroxo complex
[(h6-p-MeC6H4Pr
i)2Ru2(OH)(m-Cl)(m-SCH2-p-C6H4–NO2)], complex
2, and the dithiolato complex [(h6-p-MeC6H4Pr
i)2Ru2Cl(m-SCH2-p-
C6H4–NO2)2].2.5. Reactivity of 1–4 with cysteine and methionine
Reactions with the sulphur-containing amino acids Cys and Met
appear to play key roles in the biological chemistry of platinum(II),
platinum(IV) and ruthenium(III) anticancer agents, and were
shown to form tridentate chelates with arene ruthenium
complexes.60 The nucleophilicity of methionine is less than that of
cysteine, but still it is known to react with electrophilic sites.61,62
Upon addition of 4 eq. of Met, NMR data strongly suggest that no
reaction takes place between the mono- and dithiolato complexes
1–4 and Met. As an example, 1D 1H NMR spectra recorded at t ¼
10min and t¼ 24 h and the 2D-1H DOSY spectrum of themixture
3 : Met recorded aer 48 h are shown in Fig. S19.† Two species
can be identied in the spectrum; one with the lowest diﬀusion
coeﬃcient being the hydrolysed derivative of complex 3, the
second one being freeMet. Moreover, inspection of the 1D 1H and
2D-1H DOSY NMR spectra shows a single aH resonance and
especially a single dCH3 resonance for Met at d 2.15 ppm, sug-
gesting that there is no coordination of the methionine sulphur
atom to the Ru atom, because otherwise a characteristic high eld
shi for the dCH3 group would be expected as observed in such
complexes.63
However, upon addition of 4 eq. of Cys to the complexes 1–4,
the spectra reveal that Cys reacts rapidly with the four complexes.
In all cases, additional resonances appear immediately aer
sample preparation, indicating a rapid reaction, and equilibrium
is reached rapidly aer 2 h. As an example, the 2D-1H DOSY NMR
spectrum of the mixture 1 : Cys (ratio 1 : 3) recorded aer 24 h is
shown in Fig. 8. Three species can be clearly identied: the rst
one with the lowest diﬀusion coeﬃcient is attributed to an
“adduct” containing cysteine and the dithiolato complex, the
second species to free Cys, and the third one to acetone. A more
in-depth analysis of the 1H- and the 2D-1H DOSY NMR spectra
shows two distinct aH resonances (highlighted with a circle) at
d 3.7 and 3.8 ppm, respectively, suggesting the presence of twoRSC Adv., 2016, 6, 38332–38341 | 38337
Scheme 2 Synthesis of the cysteinato-containing complex 6, isolated
as tetraﬂuoroborate salt.
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View Article Onlinetypes of cysteine, which is cross-conrmed by their diﬀerent
diﬀusion coeﬃcient. The aH resonance at d 3.8 ppm has clearly
the same diﬀusion coeﬃcient than the p-cymene proton reso-
nances, although it appears slightly out of alignment because of
the close proximity of the intense water resonance at 4.64 ppm.
The ESI-MS spectrum shown in Fig. 9 exhibits a group of peaks
centred at m/z ¼ 887.21, which corresponds to a diruthenium
trithiolato complex containing one cysteinato bridge, [(h6-p-
MeC6H4Pr
i)2Ru2(m-SCH2CH(NH2)COOH)(m-S-m-9-B10C2H11)2]
+.
Similar results were obtained with complexes 2–4, the forma-
tion of the corresponding cysteinato-containing trithiolato
complexes as the only species present in the mixtures aer 24 h
is conrmed by both NMR and ESI-MS data (Fig. S20–S24†).
Interestingly, for both monothiolato complexes 1 and 2, the
cationic trithiolato complex [(h6-p-MeC6H4Pr
i)2Ru2{m-SCH2-
CH(NH2)COOH}2(m-SR)]
+ containing two bridging cysteinato
units, where the bridging sulphur atom of Cys occupies the
position of both the second and third bridging thiolato ligands is
the unique adduct detected aer 24 h at 37 C. Similarly, for both
dithiolato complexes 3 and 4, the cationic trithiolato complex
[(h6-p-MeC6H4Pr
i)2Ru2{m-SCH2CH(NH2)COOH}(m-SR)2]
+ contain-
ing one bridging cysteinato unit, where the bridging sulphur
atom of Cys occupies the position of the third bridging thiolato
ligand is the unique adduct detected aer 24 h at 37 C.
The in situ formation of cysteinato-containing trithiolato
complexes is somewhat surprising, since our previous attempts to
synthesise such complexes by standard methods were unsuc-
cessful; only degradation of the arene ruthenium unit was
observed. On the other hand, such complexes are conceivable in
the light of the equilibria between the thiolato complexes and the
thiol.42,43 For trithiolato complexes, the equilibria between the
thiolato complexes and the thiol do not yield cysteinato-
containing trithiolato complexes but catalyse the oxidation of
Cys to give cystine.35,43 Sadler et al. had observed the formation of
dinuclear biphenyl ruthenium complexes with cysteinato bridges
from the reaction of [(h6-C6H5Ph)RuCl(en)]
+ with Cys61 and the
formation of dinuclear p-cymene ruthenium trithiolato
complexes by reacting [(h6-p-MeC6H4Pr
i)2Ru2Cl(en)]
+ withFig. 9 ESI MS spectrum of the mixture 1 : Cys (ratio 1 : 3) dissolved in
H2O/acetone (ratio 7 : 3) recorded after 24 h in the positive mode.
38338 | RSC Adv., 2016, 6, 38332–383412-mercaptobenzanilide in aqueous solution at pH ¼ 5.3.64 We
therefore decided to modify the synthetic conditions and
attempted the synthesis and isolation of cysteinato-containing
trithiolato complexes by mimicking the conditions of the NMR
experiments. The dithiolato complex [(h6-p-MeC6H4Pr
i)2Ru2(m-
SCH2C6H4-p-Bu
t)2Cl2] (5)41 was dissolved in a small amount of
methanol and an aqueous solution of cysteine was added
dropwise in large excess. The resulting mixture was stirred at
ambient temperature for two days, and a gradual colour change
from orange to yellow was observed. The resulting product was
unstable at elevated temperature; it also degraded rapidly in
purely organic solutions. The product was therefore puried by
size exclusion chromatography on Sephadex® LH20 with
a MeOH/H2O (9 : 1) mixture, evaporated at room temperature
and dried in vacuo. Spectroscopic methods and elemental anal-
ysis proved the compound to be the tetrauoroborate salt of the
cysteinato-containing trithiolato complex [(h6-p-MeC6H4Pr
i)2-
Ru2(m-SCH2C6H4-p-Bu
t)2{m-SCH2CH(NH2)COOH}]
+ (6) (Scheme 2).
Because of its low stability, it was not possible to obtain
crystals suitable for X-rays analysis. Synthesis of the other
cysteinato-containing trithiolato complexes starting from the
dithiolato precursors 3 and 4 was also attempted, but the
resulting complexes degraded rapidly and could not be isolated
in analytically pure form. The synthesis of the cysteinato-
containing trithiolato complexes starting from the mono-
thiolato precursors 1 and 2 was not attempted.
To the best of our knowledge, together with the two di-
ruthenium complexes obtained fortuitously by Sadler et al.,61
complex 6 is only the second example of a dinuclear arene
ruthenium complex containing a cysteinato bridge. Since
intracellular biological environment contain millimolar
amounts of the tripeptide glutathione (g-Glu-Cys-Gly), such
complexes could be of considerable signicance inside cells.
This is currently being further investigated.3. Conclusions
As reported for many other arene ruthenium complexes, our
results show that the presence of chlorido ligands makes mono-
and dithiolato complexes 1–4 less stable than their trithiolato
counterparts, which do not have Ru–Cl bonds. The complexes
1–4 hydrolyse readily, though slowly in comparison with other
arene ruthenium complexes like RAPTA-C and the RAED family
of complexes. Our results also suggest that complexes 1–4
remain relatively inert towards model biomolecules and DNA,This journal is © The Royal Society of Chemistry 2016
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View Article Onlineas adducts were only observed upon addition of Cys. Interest-
ingly, unusual cationic dinuclear trithiolato complexes from
which the chlorido ligands had been removed, such as [(h6-p-
MeC6H4Pr
i)2Ru2{m-SCH2CH(NH2)COOH}(m-SR)2]
+ containing
one bridging cysteinato ligand and [(h6-p-MeC6H4Pr
i)2Ru2{m-
SCH2CH(NH2)COOH}2(m-SR)]]
+ containing two bridging cys-
teinato ligands are observed.
It can be assumed that the propensity of mono- and dithio-
lato complexes to hydrolyse and to react with sulphur-
containing molecules explains why they are at least an order
of magnitude less cytotoxic than trithiolato complexes. As
already demonstrated for mononuclear Ru(II)-arene complexes
with O,O-bound alkoxycarbonylmethyl-3-hydroxy-2(1H)-pyr-
idones,65 our results suggest that there is a negative reactivity–in
vitro cytotoxicity relationship for dinuclear thiolato-bridged
arene ruthenium complexes: the more reactive mono- and
dithiolato complexes are signicantly less cytotoxic compared
to their trithiolato counterparts. The high stability of dinuclear
arene ruthenium trithiolato complexes allows them to accu-
mulate inside the cells of a tumour,40 where they can reach their
molecular target and deploy their anticancer activity. The
monothiolato and dithiolato complexes, on the other hand, can
potentially bind to proteins and other molecules containing
sulydryl groups, which may impede their accumulation in
cancer cells in suﬃcient concentration. However, the prom-
inent examples of the arene ruthenium RAPTA complexes,
which are reactive and only exhibit a low activity in vitro, but are
very active in vivo, prompt us to further evaluate mono- and
dithiolato complexes in in vivo and preclinical models.
4. Experimental section
4.1. Materials and methods
4.1.1. Chemicals. Analytical grade chemicals obtained
from commercial suppliers were used as received. L-alanine, L-
aspartic acid, L-cysteine and L-histidine were purchased from
Acros. GSH, Sephadex® LH20 and NaOD and DCl solutions
were obtained from Sigma-Aldrich. The single-stranded DNA
dodecamer (CGCGATCGCG)2 was purchased from Microsynth.
Complexes 1–4 and 5 were prepared according to previously
published methods.42
All reactions were rst monitored by 1D 1H NMR spectros-
copy. Two-dimensional homonuclear 1H–1H and DOSY experi-
ments were performed aer 24 h of incubation at 37 C. All
experiments were carried out in aqueous solutions. The pD
values of the solutions were obtained by use of a glass electrode
and by addition of 0.41 to the pH meter reading.66,67 Oxygen was
not excluded from the solutions.
4.1.2. NMR spectroscopy. NMR data were acquired at 37 C
using a Bruker Avance II 400 MHz NMR spectrometer equipped
with a 5 mm broadband dual channel probehead
(Smartprobe®) and a Bruker Avance II 500 MHz NMR spec-
trometer equipped with an inverse triple channel (1H, 13C, 31P)
z-gradient 1.7 mm microprobehead. Both probeheads are
equipped with z-gradient accessory. One-dimensional 1H NMR
data were measured with 256 transients into 32 k data points
over the width of 12 ppm using a classic presaturation toThis journal is © The Royal Society of Chemistry 2016eliminate the water resonance. A relaxation delay of 2 s was
applied between the transients.
Two-dimensional 1H–1H COSY data were acquired over
a frequency width of 12 ppm in both F2 and F1 into 2 k complex
data points in F2 (acquisition time 213 or 170 ms) using 128 t1
increments. 32 transients were recorded per t1 increment. The
water resonance was suppressed by means of a presaturation
routine.
Two-dimensional 1H diﬀusion-ordered spectroscopy (DOSY)
NMR data were acquired with a standard longitudinal encode–
decode pulsed-eld-gradient stimulated echo sequence con-
taining bipolar gradients.68 Experimental parameters were D ¼
100 ms (diﬀusion delay), s ¼ 1 ms (gradient recovery delay) and
T ¼ 5 ms (eddy current recovery delay). For each data set, 4 k
complex points were collected, and the gradient dimension was
sampled by means of 32 experiments in which the gradient
strength was linearly increased from 1.0 to 50.8 G cm1. The
gradient duration d/2 was adjusted to observe a near-complete
signal loss at 50.8 G cm1. A 2 s recycle delay was used
between scans for the data shown. 32 transients were recorded
per experiments. For each data set, the spectral axis was pro-
cessed with an exponential function (3–5 Hz line broadening),
and a Fourier transform was applied to obtain 8 k real points.
The DOSY reconstruction was realised with 8 k complex points
in the detection dimension and with 128 points in the diﬀusion
dimension. All NMR data were processed using TopSpin
(Version 3.2, Bruker, Switzerland) and Dynamics Center
(Version 2.3.1, Bruker, Switzerland).
4.1.3. Electrospray ionisation mass spectrometry. Mass-
spectrometric (MS) analyses were performed with an LTQ
Orbitrap XL mass spectrometer (Thermo Fisher Scientic, Bre-
men, Germany) equipped with a nanoelectrospray ion source.
The samples were analysed in the positive or negative ion mode
with a voltage of +700 V applied to the glass emitter (New
Objective, Woburn, MA, USA). The tube lens was at +150 V and
the transfer capillary was held at 200 C. Spectra were acquired
in Fourier transformmass spectrometry mode over anm/z range
from 100 to 2000 with a resolution of 100 000 at m/z 400. Cali-
bration of the instrument was performed with ProteoMass LTQ/
FT-Hybrid electrospray ionisation (ESI) positive mode calibra-
tion mix (Supelco Analytical, Bellefonte, PA, USA). The Xcalibur
soware package (Version 2.0.7, Thermo Fisher Scientic) was
used for instrument control and data processing.4.2. Synthesis of the new compound [(h6-p-
MeC6H4Pr
i)2Ru2(m-SCH2C6H4-p-Bu
t)2{m-SCH2CH(NH2)
COOH}][BF4] ([6][BF4])
The dithiolato complex [(h6-p-MeC6H4Pr
i)2Ru2Cl2(m-SC6H4-p-
But)2] (5) (0.056 mmol) was dissolved in 25 mL of methanol. To
this solution, a solution of cysteine (10 eq., 0.560 mmol) in
distilled water (15 mL) was added dropwise. This mixture was
stirred at room temperature for two days. Then 10 equivalents of
NaBF4 were then added and the suspension was stirred over-
night. The solution obtained aer ltration was concentrated by
applying a vacuum at room temperature; the light orange solid
that precipitated during the evaporation was washedRSC Adv., 2016, 6, 38332–38341 | 38339
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View Article Onlinethoroughly with water and dissolved again in a MeOH/H2O
(9 : 1) mixture. The product was isolated by size exclusion
chromatography on Sephadex® LH20 from the yellow band. The
solvents were evaporated in vacuo, yielding a yellow powder.
Yield: mg (95%), ESI MS (MeOH): m/z 950.0 [M  Cl]+, C45H64-
BF4NO2Ru2S3$H2O, calcd: C, 51.27; H, 6.31; N, 1.33, found: C,
51.33; H, 6.15; N, 1.39; 1H NMR (400 MHz, CDCl3): d¼ 7.56–7.41
[m, 8H, SCH2C6H4-p-C(CH3)3], 5.57 [broad, 1H, p-CH3C6H4-
CH(CH3)2], 5.49 [broad, 1H, p-CH3C6H4CH(CH3)2], 5.46 [d, J
3 ¼
5 Hz, 1H, p-CH3C6H4CH(CH3)2], 5.32 [d, J
3 ¼ 5 Hz, 1H, p-CH3-
C6H4CH(CH3)2], 5.22 [broad, 1H, p-CH3C6H4CH(CH3)2], 5.17
[broad, 1H, p-CH3C6H4CH(CH3)2], 5.02 [broad, 1H, p-CH3C6H4-
CH(CH3)2], 4.95 [broad, 1H, p-CH3C6H4CH(CH3)2], 3.77 [m, 1H,
SCH2CH(NH2)COOH], 3.73–3.42 [m, 4H, SCH2C6H5-p-C(CH3)3],
3.01 [d, J3 ¼ 12 Hz, 1H, SCH2CH(NH2)COOH], 2.75 [m, 1H,
SCH2CH(NH2)COOH], 2.23 [m, 2H, p-CH3C6H4CH(CH3)2], 2.03
[m, 6H, p-CH3C6H4CH(CH3)2], 1.37 [s, 18H, SCH2C6H5-p-
C(CH3)3] 1.14–1.00 [m, 12H, p-CH3C6H4CH(CH3)2] ppm.
13C
NMR (100 MHz, CDCl3): d ¼ 170.55, 151.29, 129.01, 125.31,
107.18, 84.36, 83.66, 83.42, 83.22, 82.84, 82.48, 56.73, 48.63,
41.66, 40.42, 38.97, 34.20, 31.39, 22.94, 17.49 ppm.4.3. Stability of 1–4 in aqueous solution
The stability of complexes 1–4 in aqueous solutions was studied
by dissolving 1 mg of the complexes in the mixture of an
appropriate deuterated solvent and water (D2O/acetone-d6 7 : 3
for 1, D2O/acetone-d6 6 : 4 for 2 and D2O/CD3CN 7 : 3 for 3 and
4). The pD of the solutions was varied by adding NaOD, phos-
phate buﬀer or DCl. The solutions were subsequently trans-
ferred to 1.7 mm NMR tubes and 1D 1H-NMR experiments were
recorded at 37 C aer 5 min, 30 min, 1 h, 2 h, 3 h, and every two
hours until 24 h. An additional spectrumwas also systematically
recorded aer 48 or 72 h.4.4. Interactions of 1–4 with amino acids
1 mg of the respective complex was dissolved in the appropriate
aqueous solution (vide supra). When the hydrolysis reactions
had reached a steady state, three to four equivalents of amino
acid (Ala, Asp, Cys, Met or His) were added. The solutions were
then transferred into NMR tubes and 1D 1H-NMR experiments
were measured at 37 C aer 5 min, 30 min, 1 h, 2 h, 3 h and
every two hours until 24 h. An additional spectrum was also
systematically recorded aer 48 or 72 h. ESI-MS, 2D 1H–1H
COSY and 2D 1H-DOSY NMR spectra were recorded aer the last
1D 1H-NMR experiment. Between the measurements, the tubes
were stored in the incubator at 37 C.4.5. Interactions of 1–4 with the single stranded DNA
dodecamer
Interaction of complexes with the single-stranded DNA
dodecamer (CGCGATCGCGGCGCTAGCGC) was studied by dis-
solving the complexes in appropriate aqueous solution (vide
supra), adding 1 mg of DNA fragment (Mw ¼ 6119.2) and incu-
bating the mixture at 37 C. MS measurements were performed
aer 2 h and 24 h of incubation.38340 | RSC Adv., 2016, 6, 38332–38341Acknowledgements
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